Silexion Therapeutics Corp. will be presenting at the Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 3, 2025. The presentation will be led by CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar at Florida Atlantic University Conference Center in Boca Raton, FL. Interested parties can schedule one-on-one meetings with Silexion’s management during the conference. The company, focused on developing treatments for solid tumor cancers with mutated KRAS oncogene, recently conducted a Phase 2a clinical trial showing positive results. For more information, visit their website at silexion.com. Investors can contact the company at [email protected] or through Arx Investor Relations and LifeSci Advisors.

Read more at GlobeNewswire: Silexion Therapeutics to Present at Noble Capital Markets’